Smoking Cessation’s Quiet Design Failure

Fewer than one in ten smokers who try to quit each year succeed. That number has barely moved in two decades. When 90 out of every 100 motivated quit attempts consistently fail, it’s clear the failure is structural.

The standard explanation is that quitting is hard: a failure of motivation, environment, or follow-through. But after decades of watching the same cessation tools produce the same disappointing results, the problem is starting to look less like the patients and more like the tools.

The category of smoking cessation has a two-part design problem. Most of what clinicians prescribe or recommend today is pharmacology that underperforms in the real world, built for a patient who no longer exists, and in some ways never did. 

Treatments built for yesterday’s smoker

The dominant cessation therapies — nicotine replacement, prescription medications, behavioral counseling — were developed in an era when nicotine use was relatively uniform. A patient smoked a fairly predictable number of cigarettes per day, at fairly predictable times, with a fairly predictable dose curve. Treatments were designed around that pattern: fixed daily doses, slow and steady delivery, standardized behavioral protocols.

That patient is increasingly rare. Today’s nicotine user often moves between cigarettes, e-cigarettes, pouches, and other products, sometimes within a single day. Consumption tends to be more frequent, more situational, and closer to continuous, with doses absorbed throughout the day rather than organized around the rituals of a pack of cigarettes.

This is a major shift. It changes the pharmacology of dependence, the behavioral loops that reinforce use, and the moments when relapse is most likely. A therapy calibrated to a pack-a-day smoker is not going to map cleanly onto someone who hits a pouch every twenty minutes.

And even for the more uniform patient the therapies were originally built around, the pharmacology was the weaker half of the design. The decades-old nicotine medications still in use today are largely ineffective in the real world. They are “low and slow,” delivering inadequate levels of nicotine at a pace that can’t compete with a combustible cigarette. The therapy and the addiction have never operated at the same speed, and that gap is a meaningful part of why so few quit attempts succeed.

The limits of layering

The response from much of the field has been to add things on top. A companion app. A telehealth coaching layer. Digital reminders stapled to a decades-old pharmacological regimen.

The evidence on these additions is mixed. Some studies show meaningful gains when apps are paired with pharmacotherapy; others show no difference at all. What’s consistent is that the wins tend to be modest, inconsistent across populations, and heavily dependent on engagement that most users don’t sustain. Patients open the app for a few weeks. Whether they quit is another question.

The problem is that the underlying therapy has no way to act on what the digital layer observes. If an app flags that a patient tends to relapse on weekday afternoons, the nicotine patch on their arm can’t do anything about it. The treatment and the data sit in separate systems, with a clinician, if one is even in the loop, as the only connection between them.

What an integrated therapy would actually do

A treatment regimen designed for how nicotine is used now would look different from the start. It would deliver nicotine in higher doses and at faster onset. It would capture patterns of use, timing, frequency, context, all as part of the therapy itself, not as an add-on. It would adjust delivery based on those patterns rather than running on a fixed schedule. It would give clinicians real-time information about when a patient is struggling and when tapering is working, rather than relying on self-report at a follow-up visit weeks later.

There’s a difference between tools that track behavior and tools that act on it. Most of what’s reached the market does the first. The category has yet to produce much of the second.

Building therapies this way is harder. It requires pharmacology, device engineering, and behavioral science to develop together rather than get bolted on in sequence, and it asks investors and developers to bet on integration rather than iteration. The easier path is to keep shipping refinements of the same decades-old therapies. That’s also why quit rates haven’t moved.

The stakes of standing still

Roughly 30 million American adults still smoke. More than 480,000 of them will die from it this year. The gap between how nicotine use has evolved and how cessation treatment has evolved is a meaningful part of why quit rates have plateaued.

Even small improvements compound at this scale. A few percentage points of additional efficacy across the smoking population translates into millions of fewer smokers, a substantial reduction in tobacco-related disease, and healthcare savings measured in tens of billions of dollars.

Getting there won’t come from another app bolted onto another patch. It will come from treating smoking cessation as a design problem, and being willing to rebuild the therapies, not just the packaging around them.

Photo: artisteer, Getty Images

This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.